CliffBio
small molecule

TRYNGOLZA (AUTOINJECTOR)

OLEZARSEN SODIUM

Loss of exclusivityMay 2034latest FDA-listed patent expiry
CompanyIonis Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameTRYNGOLZA (AUTOINJECTOR)
Active ingredientOLEZARSEN SODIUM
StrengthEQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML)
Dosage formSOLUTION
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalDecember 2024
Marketing statusRX

Listed patents

PatentExpiresType
12509684May 2034use U-4580
9181549May 2034substance
9163239May 2034substance
9127276May 2034substance
9593333February 2034use U-4050
9157082April 2032use U-4580

Regulatory exclusivity

CodeExpires
ODE-515December 2031
I-992June 2029

More from Ionis Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.